SIRT2 and breast carcinoma: first identified that it deacetylates Slug protein at lysine residue K116 to prevent Slug degradation driving the acquisition of aggressive basal‐like phenotypes and promoting tumor growth in breast cancer.[18] Likewise, our findings also supported that SIRT2 deacetylates Slug at K116 in ovarian cancer.